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Background: We sought to evaluate life expectancy and mortality of HIV-positive individuals initiating combination
antiretroviral therapy (ART) across Canada, and to consider the potential error introduced by participant loss to
follow-up (LTFU).
Methods: Our study used data from the Canadian Observational Cohort (CANOC) collaboration, including HIV-positive
individuals aged ≥18 years who initiated ART on or after January 1, 2000. The CANOC collaboration collates data from
eight sites in British Columbia, Ontario, and Quebec. We computed abridged life-tables and remaining life expectancies
at age 20 and compared outcomes by calendar period and patient characteristics at treatment initiation. To correct for
potential underreporting of mortality due to participant LTFU, we conservatively estimated 30 % mortality among
participants lost to follow-up.
Results: 9997 individuals contributed 49,589 person-years and 830 deaths for a crude mortality rate of 16.7 [standard
error (SE) 0.6] per 1000 person-years. When assigning death to 30 % of participants lost to follow-up, we estimated
1170 deaths and a mortality rate of 23.6 [SE 0.7] per 1000 person-years. The crude overall life expectancy at age 20 was
45.2 [SE 0.7] and 37.5 [SE 0.6] years after adjusting for LTFU. In the LTFU-adjusted analysis, lower life expectancy at age
20 was observed for women compared to men (32.4 [SE 1.1] vs. 39.2 [SE 0.7] years), for participants with injection drug
use (IDU) history compared to those without IDU history (23.9 [SE 1.0] vs. 52.3 [SE 0.8] years), for participants reporting
Aboriginal ancestry compared to those with no Aboriginal ancestry (17.7 [SE 1.5] vs. 51.2 [SE 1.0] years), and for
participants with CD4 count <350 cells/μL compared to CD4 count ≥350 cells/μL at treatment initiation (36.3
[SE 0.7] vs. 43.5 [SE 1.3] years). Life expectancy at age 20 in the calendar period 2000–2003 was lower than in
periods 2004–2007 and 2008–2012 in the LTFU-adjusted analyses (30.8 [SE 0.9] vs. 38.6 [SE 1.0] and 54.2 [SE 1.4]).
Conclusions: Life expectancy and mortality for HIV-positive individuals receiving ART differ by calendar period
and patient characteristics at treatment initiation. Failure to consider LTFU may result in underestimation of mortality
rates and overestimation of life expectancy.
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Twenty-five years since the World Health Organization
announced the Global Program on AIDS to respond to
the HIV/AIDS pandemic, an HIV cure remains elusive
[1]. Recent reports estimate that 35 million people live
with HIV globally, and this figure continues to increase
[2]. That being said, treatment options available to indi-
viduals living with HIV have significantly improved in
efficacy, safety and tolerability over the last decade.
There is global consensus that combination antiretro-
viral therapy (ART) decreases mortality and morbidity
among the HIV-positive population [3–5]; and new ap-
proaches in ART delivery, such as PI boosting and
fixed-dose combinations, are thought to improve treat-
ment outcomes [6]. The improving efficacy of ART reg-
imens has resulted in the recognition of HIV as a
chronic, manageable condition.
At the end of 2011 there were approximately 71,300
people living with HIV/AIDS in Canada [7]. Antiretroviral
regimens have been available to Canadian residents
eligible for treatment since the mid-1980s. Treatment
provision and coverage vary across Canada, depending
on the provincial and territorial programs imple-
mented. With improvements in treatment regimen ac-
cess, uptake and efficacy, the mortality and morbidity
of HIV-positive persons have significantly decreased
over time [8, 9]. However, despite widespread availabil-
ity of more efficacious ART regimens, life expectancy
(an important population health indicator) remains
lower for HIV-positive individuals compared with the gen-
eral population [8]. Additionally, other non-AIDS defining
comorbidities are of increasing concern for HIV-positive
individuals accessing ART; including malignancy, cardio-
vascular disease, pulmonary disease, liver disease, and
renal disease [10, 11]. These comorbidities are hypothe-
sized to occur at a higher rate among people living with
HIV due to immunodeficiency [10], inflammation [12], a
higher prevalence of behavioural risk factors [10], viral co-
infections and the toxicity of antiretroviral regimens [13].
The effect of HIV on life expectancy in the era of
ART is not well explored in the Canadian context.
Similarly, the effect of baseline characteristics, such as
sex and HIV transmission risk group, on life expect-
ancy and mortality among treatment-experienced
individuals has not yet been defined for our region.
This analysis sought to evaluate life expectancy and
mortality rates of HIV-positive individuals accessing
antiretroviral regimens across three Canadian prov-
inces, comparing outcomes in the modern treatment
era by calendar year and by subgroups defined by pa-
tient characteristics at treatment initiation. In addition,
we sought to consider the potential error introduced in
mortality analyses due to loss to follow-up (LTFU) of
cohort participants.Methods
Data source
The Canadian Observational Cohort (CANOC) collab-
oration is a pan-provincial cohort of HIV-positive indi-
viduals initiating ART naively, established to evaluate
patterns of treatment uptake and response, and health
service provision and outcomes across Canada. CANOC
consists of eight cohorts from the provinces of British
Columbia, Ontario and Quebec. Each cohort site performs
data extraction of demographic, laboratory and clinical
variables of interest and annually submits these data to the
coordinating centre in Vancouver, British Columbia. A de-
tailed CANOC profile was published in 2011 [14].Ethics statement
Ethics board approval of the CANOC collaboration was
granted by the Simon Fraser University Research Ethics
Board (REB) and the University of British Columbia REB.
Additionally, approval from local institutional review
boards (IRBs) was granted at each participating cohort
site, including: Providence Health Care Research Institute
Office of Research Services, the Ottawa Hospital REB,
University Health Network (UHN) REB, Véritas IRB,
Biomedical C REB of the McGill University Heath Centre
(MUHC), University of Toronto HIV REB, and Women’s
College Hospital REB.
Written consent for study participation has been
obtained from all study cohorts except: HAART Obser-
vational Medical Evaluation and Research Cohort (IRB
approves the retrospective use of anonymous adminis-
trative data without requiring consent; an information
sheet is provided in lieu of a consent form); Ottawa
Hospital Cohort, UHN and Maple Leaf Medical Clinic
(IRB/REBs approve the anonymous use of data retro-
spectively extracted from clinical care databases with-
out requiring consent); and MUHC and the Electronic
Antiretroviral Therapy Cohort (IRB/REBs approve the
anonymous use of data retrospectively extracted from
clinical care databases without requiring consent; pa-
tients sign a general waiver on opening a medical chart
at the hospital but no specific study related consent).Inclusion criteria
CANOC includes individuals with documented HIV
infection, aged at least 18 years, and currently resident
in Canada. Participation is restricted to formerly ART-
naive HIV-positive individuals initiating combination
ART on or after 1 January 2000. All participants had
baseline CD4 cell count and viral load measurements
(within six months prior to ART initiation). This ana-
lysis included individuals enrolled in CANOC from
2000–2012.
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The primary outcome of interest was date of death from
all-causes, used to assess mortality rates and life expect-
ancy. Demographic and clinical characteristics of interest
included sex, Aboriginal ancestry, baseline CD4 cell
count and HIV transmission group (injection drug use
(IDU) history vs. no IDU history).
This analysis compared life expectancy among HIV-
positive individuals on ART in Canada over three calendar
periods, based on year of ART initiation (2000–2003,
2004–2007 and 2008–2012). We also considered differ-
ences in mortality rates and life expectancy in subgroups
defined by patient characteristics at initiation of treatment.
Crude and age-specific mortality rates were calculated.
Mortality rates (per 1000 person-years) were calculated by
dividing the total number of deaths by the total number of
person-years of follow-up; we report these results with
standard errors, calculated using Poisson distribution.
Mortality rates were stratified by sex (male vs. female),
Aboriginal ancestry (Aboriginal vs. non-Aboriginal), HIV
transmission risk group (IDU history vs. no IDU history),
and baseline CD4 count (<350 and ≥350 cells/μL). Where
the data set was incomplete, analyses were restricted to
cohort participants with non-missing information.
Abridged life tables were constructed from age-specific
mortality rates to compare life expectancy at the age of
20 years in the three designated calendar periods under
study. Life expectancy at age 20 refers to the number of
remaining years a participant would be expected to live.
Abridged life tables constructed for this analysis were
based on widely used and standardized methods [15]. We
partitioned each individual’s total person-time contribu-
tion and deaths into five-year age categories to compute
abridged life tables and life expectancies with correspond-
ing standard errors [SE]. Due to the relatively small
proportion of participants within older age categories, the
final age category constructed within the life tables was 55
+ years. Life expectancy values at the exact age of 20 years
were reported for the whole cohort as well as stratified by
sex, transmission group, Aboriginal ancestry and CD4 cell
count at treatment initiation.
Estimation of potential error due to LTFU
For the purposes of this analysis, LTFU was defined as the
last recorded known contact date being more than
18 months before the end of the study period. To correct
for potential misclassification of death among persons
recorded as lost to follow-up (and differences in ascertain-
ment rates between individual cohorts/provinces), we con-
servatively estimated that 30 % of participants who were
lost to follow-up had died. This estimate was recently used
in a mortality analysis conducted within the Antiretroviral
Therapy Cohort Collaboration (ART-CC) [16], chosen to
reflect the findings of a survey evaluating mortality amongthose lost to follow-up within the French hospital data-
base on HIV infection (FHDH) [16, 17]. Our 30% esti-
mate is consistent with published literature describing
mortality rates among HIV-positive participants lost to
follow-up in a Ugandan setting, ranging from 28–29 %
[18–20], and Canadian estimates of mortality rates
among HIV-hepatitis C co-infected participants lost to
follow-up, reported at 40 % [21].
Among participants not lost to follow-up, a multivari-
able logistic regression model (containing demographic
and clinical characteristics) was created, with death as
the outcome variable. The resulting parameter estimates
were then applied to those lost to follow-up, which
generated estimated probabilities of death for these lost
patients, of which the highest 30 % were categorized as
deaths. Date of death was recorded as the last contact
date for participants lost to follow-up who were assigned
the outcome.Results
Baseline characteristics of the 9997 participants within
the analytic sample are presented in Table 1. The cohort
was predominantly male (82 %), with a history of IDU
reported by 27 % of participants. The median baseline
age was 40 (interquartile range (IQR): 33–47), with 10 %
of participants reporting Aboriginal ancestry. Of the
9350 participants with available data on hepatitis C
status, 26 % were hepatitis C positive. Notably, among
participants with a history of IDU the prevalence of
hepatitis C infection was 82 %, compared to 7 % among
participants with no IDU history (p < 0.001).Loss to follow-up
The median follow-up time within the cohort was
52 months (IQR: 24–89). Overall, 11 % of all participants
were lost to follow-up during the study period. Table 2
compares the clinical and sociodemographic characteris-
tics at treatment initiation for participants retained within
the cohort and participants lost to follow-up. Participants
lost to follow-up were more likely to be female, report no
IDU history, report no Aboriginal ancestry and have a
CD4 count <350 cells/μL at treatment initiation, as com-
pared to participants retained in the cohort (all p <0.05).
Table 3 compares the clinical and sociodemographic char-
acteristics at treatment initiation for participants lost to
follow-up who were assigned and not assigned the out-
come death. Participants assigned the outcome death were
more likely to report IDU history and Aboriginal ancestry,
and have a CD4 count <350 cells/μL at treatment initi-
ation (all p < 0.001). In all analyses, adjusting for mor-
tality among cohort participants lost to follow-up
decreased the estimated life expectancy and increased
the estimated mortality rate, as expected.
Table 2 Clinical and sociodemographic characteristics at
treatment initiation for participants retained within the cohort and
participants lost to follow-up (n = 9997)
Characteristic Total (n) Not lost to
follow-up (%)
Lost to
follow-up (%)
P-value
All Participants 9997 8865 (88.7) 1132 (11.3)
Sex 0.044
Female 1831 1599 (87.3) 232 (12.7)
Male 8166 7266 (89.0) 900 (11.0)
History of IDUa <0.001
Yes 2141 1964 (91.7) 177 (8.3)
No 5702 5051 (88.6) 651 (11.4)
Aboriginal
ancestryb
0.001
Yes 467 437 (93.6) 30 (6.4)
No 4275 3788 (88.6) 487 (11.4)
CD4 cell count
(cells/μL)
0.002
<350 7689 6777 (88.1) 912 (11.9)
≥350 2308 2088 (90.5) 220 (9.5)
IDU injection drug use
an = 7843
bn = 4742
Table 1 Demographic and clinical characteristics of participants,
overall and by calendar year of ART initiation (n = 9997)
Period 1 Period 2 Period 3 Overall
(2000–2003) (2004–2007) (2008–2012) (2000–2012)
n = 2381 n = 3058 n = 4558 n = 9997
(%) (%) (%) (%)
Baseline
age
18–34 693 (29.1) 791 (25.9) 1459 (32.0) 2943 (29.4)
35–44 1034 (43.4) 1297 (42.4) 1518 (33.3) 3849 (38.5)
45–54 481 (20.2) 718 (23.5) 1145 (25.1) 2344 (23.4)
55+ 173 (7.3) 252 (8.2) 436 (9.6) 861 (8.6)
Sex
Female 480 (20.2) 591 (19.3) 760 (16.7) 1831 (18.3)
Male 1901 (79.8) 2467 (80.7) 3798 (8303) 8166 (81.7)
History
of IDUa
Yes 592 (31.0) 719 (29.5) 830 (23.7) 2141 (27.3)
No 1315 (69.0) 1721 (70.5) 2666 (76.3) 5702 (72.7)
Aboriginal
ancestryb
Yes 150 (10.6) 151 (9.7) 166 (9.4) 467 (9.8)
No 1266 (89.4) 1410 (90.3) 1599 (90.6) 4275 (90.2)
CD4 cell count
(cells/μL)
<350 2024 (85.0) 2679 (87.6) 2986 (65.5) 7689 (76.9)
≥350 357 (15.0) 379 (12.4) 1572 (34.5) 2308 (23.1)
Analyses restricted to those with non-missing data
IDU injection drug use
an = 7843
bn = 4742
Table 3 Clinical and sociodemographic characteristics at
treatment initiation for participants assigned to the outcome
death and not assigned to death among those lost to follow-up
(n = 1132)
Characteristic Total (n) Not assigned
death (%)
Assigned
death (%)
P-value
Participants lost
to follow-up
1132 792 (70.0) 340 (30.0)
Sex 0.787
Female 232 164 (70.7) 68 (29.3)
Male 900 628 (69.8) 272 (30.2)
History of IDUa <0.001
Yes 177 53 (29.9) 124 (70.1)
No 651 538 (82.6) 113 (17.4)
Aboriginal
ancestryb
<0.001
Yes 30 13 (43.3) 17 (56.7)
No 487 379 (77.8) 108 (22.2)
CD4 cell count
(cells/μL)
<0.001
<350 912 604 (66.2) 308 (33.8)
≥350 220 188 (85.5) 32 (14.5)
IDU injection drug use
an = 828
bn = 517
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9997 individuals contributed 49,589 person-years and
830 deaths for an overall crude mortality rate of 16.74
[SE 0.58] per 1000 person-years (Table 4). After esti-
mating 30 % mortality among participants lost to
follow-up, there were 1170 deaths, with a mortality rate
of 23.59 [SE 0.69] per 1000 person-years. Unadjusted
and adjusted mortality rates, overall and by select char-
acteristics, are presented in Table 4. In both unadjusted
and LTFU adjusted analyses, female sex, IDU history,
Aboriginal ancestry and CD4 count of <350 cells/μL at
treatment initiation were significantly associated with
increased mortality.
Life expectancy
Unadjusted life expectancy at age 20 was 45.2 [SE
0.66], and 37.5 [SE 0.61] years after estimating 30 %
mortality among those lost to follow-up (Table 5). In
both unadjusted and LTFU adjusted analyses, female
sex, IDU history, Aboriginal ancestry and CD4 count
Table 4 Population size, deaths, and unadjusted and adjusted
mortality rate per 1000 person-years (PY), overall and by select
characteristics
Populationa Deaths Person
Years
(PY)
Unadjusted
mortality
rate per
1000PY (SE)
Adjustedb
mortality
rate per
1000PY(SE)
Overall 9997 830 49588.88 16.74 (0.58) 23.59 (0.69)
Sex
Female 1831 184 9303.73 19.78 (1.46) 27.09 (1.71)
Male 8166 646 40285.14 16.04 (0.63) 22.79 (0.75)
History of
IDU
Yes 2141 377 11082.71 34.02 (1.75) 45.21 (2.02)
No 5702 257 28875.05 8.90 (0.56) 12.81 (0.67)
Aboriginal
ancestry
Yes 467 123 2398.97 51.27 (4.62) 58.36 (4.93)
No 4275 255 24627.65 10.35 (0.65) 14.74 (0.77)
Baseline CD4
(cells/μL)
<350 7689 740 41016.06 18.04 (0.66) 25.55 (0.79)
≥350 2308 90 8572.82 10.50 (1.12) 14.23 (1.29)
Year of ART
initiation
2000–2003 2381 399 20389.75 19.57 (0.98) 31.29 (1.24)
2004–2007 3058 287 17928.23 16.01 (0.95) 21.03 (1.08)
2008–2012 4558 144 11270.90 12.78 (1.07) 13.75 (1.11)
SE standard error, IDU injection drug use, ART antiretroviral therapy
aAnalyses restricted to those with non-missing data
bIncluding assumed 30 % mortality in participants lost to follow-up
Table 5 Life expectancy estimates at age 20 years, showing
unadjusted and adjusted values (assuming 30 % mortality among
those lost to follow-up), n = 9997
Unadjusted Adjusted
eOx (SE) eOx (SE)
Overall 45.2 (0.66) 37.5 (0.61)
Sex
Female 40.1 (1.34) 32.4 (1.12)
Male 47.0 (0.75) 39.2 (0.72)
History of IDU
Yes 28.2 (1.07) 23.9 (0.96)
No 63.9 (0.92) 52.3 (0.84)
Aboriginal ancestry
Yes 19.1 (1.60) 17.7 (1.49)
No 62.7 (1.12) 51.2 (0.97)
Baseline CD4 (cells/μL)
<350 44.1 (0.77) 36.3 (0.70)
≥350 50.8 (1.35) 43.5 (1.25)
Year of ART initiation
2000–2003 40.8 (1.05) 30.8 (0.90)
2004–2007 44.4 (1.04) 38.6 (0.96)
2008–2012 56.7 (1.43) 54.2 (1.37)
eox life expectancy estimate (years), SE standard error, IDU injection drug use,
ART antiretroviral therapy
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cantly associated with decreased life expectancy at age
20 (Table 5, Fig. 1).
Temporal trends
Both life expectancy and mortality rates improved over
time (Tables 4 and 5, Fig. 1). Mortality rates decreased
within more recent time periods, both before and after
adjusting for mortality among participants lost to follow-
up (Table 4). Life expectancy at age 20 increased within
more recent time periods in both the unadjusted and
adjusted analyses, reaching a maximum life expectancy of
54.2 [SE 1.37] years in the period 2008–2012, after adjust-
ing for mortality among participants lost to follow-up
(Table 5).
Sensitivity analysis
Given that only 8.6 % (n = 861) of our analytic sample was
aged 55+ years (contributing a total of 3903.8 person-
years of follow-up) we were concerned that mortality rates
among participants within this age category, especially
at the oldest ages, may be underestimated, potentiallyinflating the life expectancy estimates generated. To
explore this issue, we conducted a sensitivity analysis using
2006 mortality data for the general Canadian population to
obtain revised life expectancy estimates [22]. We assumed
that the rise in the mortality rate between participants aged
50–54 and participants aged 55+ years in our analytic sam-
ple would increase by the same ratio as that demonstrated
within the general Canadian population of corresponding
age categories. Based on this assumption, we extrapolated
the mortality rates observed among study participants aged
50–54 to produce new mortality estimates for participants
aged 55+ years. After performing this adjustment, the over-
all life expectancy at age 20 decreased from 45.2 [SE 0.7]
years to 31.7 [SE 0.4] years (Additional file 1).
Discussion
The largest of its kind conducted in Canada to date,
our study contributes a number of important findings
on life expectancy among HIV-positive persons in this
region. Specifically, we observed that life expectancy
and mortality for HIV-positive individuals accessing
ART differ by sex, IDU history, Aboriginal ancestry,
baseline CD4 cell count prior to ART initiation, and
calendar period of ART initiation. Additionally, this
manuscript employs a novel methodological approach
to life expectancy analyses; questioning the validity of
Fig. 1 Life expectancy estimates at age 20 years, showing unadjusted and adjusted values, by clinical and sociodemographic characteristics at baseline
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ticipants lost to follow-up and those that lack sufficient
follow-up data among older individuals accessing treatment.
Life expectancy within this cohort improved with more
recent calendar periods. This finding has been previously
reported in the literature, and likely reflects improved
coverage and quality of ART regimes and HIV care [4, 5,
23, 24]. Recent reports estimate the average remaining life
expectancy for Canadians at age 20 to be 59.7 and
63.9 years for men and women, respectively [25]. When
compared with the findings of our study, it is clear that
despite advances in the health care services and antiretro-
viral therapies available to people living with HIV in
Canada, the life expectancy of HIV-positive Canadians re-
mains lower than that of the general population.
Men demonstrated longer life expectancy and lower
mortality rates compared to women in this cohort. This is
in contrast to population-level surveillance data published
by Statistics Canada, reporting increased life expectancy
among women compared with men in the general popula-
tion in all Canadian provinces [26]. A recent publication
evaluating regional and sex specific patterns of HIV/AIDS
mortality in Canada from 1987-2008 found that age-
specific death rates among women in most age categories
were lower than those observed among men [27]. How-
ever, this study observed that the decline in HIV-related
mortality rates since the mid-1990s was much more pro-
nounced among men than women. North American pub-
lications evaluating mortality in HIV-positive cohortsaccessing ART have demonstrated comparable sex-related
differences to those shown in our study [9, 28, 29].
However, mortality analyses conducted in European
and trans-continental settings have observed contrasting
sex differences among HIV-positive cohorts, depicting a
longer life expectancy among women than men [8, 30, 31].
Other studies have found no sex-related differences [32].
These inconsistencies may be due to inherent differences
in cohort demographics, treatment access and healthcare
utilization. A recent publication commented on the validity
of cross-cohort comparisons of mortality rates, suggesting
that cohort characteristics in different settings can signifi-
cantly alter HIV outcomes, including mortality [16]. In re-
cent years, Canadian studies have reported disparities in
retention within key stages of the HIV treatment cascade,
including access and adherence to treatment and achieve-
ment of viral suppression, according to region of care [33],
sex and IDU history [33, 34]. In these studies, women and
individuals with a history of IDU demonstrated decreased
retention within the HIV treatment cascade in Canada
[33, 34]. In CANOC, a disproportionate number of HIV-
positive individuals reporting IDU history are women,
which reflects the composition of the Canadian HIV epi-
demic, especially in British Columbia.
Individuals with a history of IDU demonstrated poor
mortality and life expectancy outcomes in this analysis.
This finding has been consistently reported in the pub-
lished literature [8, 9, 23, 29, 35]. Previous studies have
shown that the increased mortality rates among
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of all-cause mortality, rather than HIV-related mortality
[35, 36]. Indeed this demographic group experiences a
high prevalence of comorbidities, augmented by poten-
tial active drug use, socioeconomic disadvantage and
poor access to health care services [36]. In our study
cohort, a significantly higher prevalence of hepatitis C
infection was identified among participants with a his-
tory of IDU compared to individuals with no IDU his-
tory. Infection with hepatitis C is an important
contributor to mortality and morbidity among people
living with HIV, primarily due to an increased risk of
liver disease [37, 38]. A recent Canadian cohort study
reported notably higher mortality rates among individ-
uals co-infected with HIV and hepatitis C compared to
previously published mortality rates among mono-
infected HIV-positive individuals [39].
CD4 cell count at treatment initiation was another sig-
nificant predictor of mortality and life expectancy in our
cohort. Participants with CD4 cell counts <350 cells/μL at
treatment initiation demonstrated increased mortality rates
and decreased life expectancy. This finding is consistent
with previous mortality studies [8, 9], and reinforces the
long-term health benefits of ART initiation earlier in the
course of HIV infection. Earlier ART initiation is supported
by the 2014 International Antiviral Society-USA guidelines,
recommending the initiation of antiretroviral therapy re-
gardless of CD4 cell count for most patients [40].
In our analysis, we found Aboriginal ancestry to be pre-
dictive of decreased life expectancy. This is consistent with
a Canadian retrospective cohort study published in 2011,
which reported that individuals of Aboriginal descent re-
ceiving ART demonstrate increased all-cause and HIV-
related mortality rates compared with non-Aboriginal
people living with HIV in Canada [35]. This observation
may be due to competing life circumstances and social-
structural factors that influence access and adherence to
ART among Aboriginal persons [35]. A report by Statistics
Canada similarly identified this difference in life
expectancy between Canadians of Aboriginal ancestry and
the non-Aboriginal population [41]. This observation is
concerning, and initiatives to improve treatment outcomes
of Aboriginal Canadians should be made a priority. To
note, this finding may be influenced by underlying charac-
teristics of our cohort, as a disproportionate number of
HIV-positive individuals reporting IDU history in CANOC
also report Aboriginal ancestry.
Large-scale longitudinal cohort studies often face a
significant limitation in the form of incomplete data due
to participant LTFU. LTFU affects most cohort studies
and can result in bias, affecting study validity [42]. In
conducting this study we sought to account for the im-
pact of LTFU on life expectancy estimates to reduce po-
tential bias and improve the validity of our findings.After conservatively estimating 30 % mortality among
participants lost to follow-up, unsurprisingly we observed
that mortality rates increased and life expectancy esti-
mates decreased. This suggests that failure to account for
participant lost to follow-up in mortality analyses results
in the potential for significant underestimation of mortal-
ity rates and overestimation of life expectancy data, affect-
ing data validity.Limitations
Several limitations of this study should be acknowledged.
CANOC includes data from only three Canadian prov-
inces, and participants included are already linked to
specific health care facilities, therefore the analytic sample
is not be fully representative of the overall HIV-positive
population across Canada, including those most at risk of
adverse clinical outcomes. Data from British Columbia
include all CANOC-eligible HIV-positive individuals in
the province accessing ART, whereas data from Ontario
and Quebec are collected from a selection of clinics,
which may introduce a clinic-selection bias. This study
considers the Canadian HIV-positive population, therefore
observations described may not be generalizable to other
global settings.
We conducted an adjusted analysis to account for
misclassification of mortality among participants lost to
follow-up, conservatively estimating the death of 30 %
of those lost to follow-up. As published data concern-
ing mortality among participants lost to follow-up in
Canadian cohorts are limited, this estimate was based on
previous European [17] and Ugandan studies among HIV-
positive cohorts [18–20] and findings from a Canadian
cohort of HIV-hepatitis C co-infected individuals [21].
Therefore, this estimate may not be entirely generalisable
to all HIV-positive individuals in Canada. Further studies
may seek to evaluate how accurate our assumption was
regarding mortality among HIV-positive participants lost
to follow-up in this setting. Differences in mortailty ascer-
tainment by site also exist, and thus our estimation of
mortality may be more problemetic at sites that do not
link to vital statistics registries.
Another potential limitation of this study was that we
did not allow for censoring in LTFU data. This is
particularly relevant for those who initiated ART in the
most recent time period; in some cases not enough
time had passed to be declared lost to follow-up given
the 18-month definition. Unfortunately, data describing
causes of death are not currently collected across par-
ticipating cohorts in the CANOC collaboration; as such
we were unable to present the distribution of causes of
death within this manuscript.
Given that only a small proportion of our analytic
sample was aged ≥55 years, we conducted a sensitivity
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Canadian population to explore whether possible
underestimation of mortality rates among participants
within this age category affected the life expectancy
values generated. The results suggested that our life ex-
pectancy estimates may be overestimated due to impre-
cise representation of mortality rates within older age
categories. As the Canadian population living with HIV
ages, the reliability of results generated by life expect-
ancy analyses such as this will continue to improve.
Conclusion
In conclusion, this study found that while both mortality
rates and life expectancy for HIV-positive Canadians
accessing ART are improving over time, they remain
below that of the general Canadian population. Life
expectancy and mortality are influenced by baseline
characteristics at treatment initiation, including Aboriginal
ancestry, sex, CD4 cell count and IDU history. These
findings suggest the need for targeted interventions for
patient subgroups at increased risk of adverse outcomes.
Future studies examining patterns of life expectancy and
mortality among HIV-positive populations should take into
account mortality among participants lost to follow-up to
ensure validity of estimates.
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